




Henlius

复宏汉霖

年 月

宏·进化



CONTENTS

01

02

03



04

01





Biotech

Partial function setup

Singular/few products

In-licensing dependent

Thin revenue, cash burning

Lack of system, highly rely on founder

H-evolution



Biopharma

Full value chain

Comprehensive portfolio

Mostly organic, supplemented with external



Sizable revenue, self financing

Strategic/systematic governance


战略目标




02











3.1









12+9





20+.














3.2





2022 年中期 投入商业化生产

+24,000L

HLX02 汉曲优® 工艺升级

x12 倍



成功实现端对端连续化生产

x12 倍




96!999 L


2021工程建设已全面加速

3.3






以患者为中心的化债战略同时注重运营效率，实现健康和可持续的发展




DTP









60mg **2022**


®150/60mg








2022


























04





保持整体投入，提升研发效率，创新药投入占比提升



保持整体投入，提升研发效率

强化临床运营团队，建立汉霖自己的临床优势储备，逐步减少外部CRO供应商，转为依靠内部资源，节约成本。

积极开展推动创新新研发项目的同时，通过研发降本增效节约部分抵消开支

报告期内加速推进覆盖CD38、CD73、LAG-3、EGFR×4-1BB、PD-L1×TIGIT靶点临床前研究项目的IND。

国际多中心临床项目高效推进

HLX04-O (VEGF) 治疗湿性年龄相关性黄斑变性3期IND获澳大利亚、美国、拉脱维亚、新加坡、西班牙、捷克、波兰等欧盟国家批准

国内临床项目进展顺利

斯鲁利单抗 (PD-1) + 汉贝泰® (VEGF) 治疗肝细胞癌2期临床研究受试者入组完成

斯鲁利单抗 (PD-1) + 汉贝泰® (VEGF) + 化疗治疗转移性结直肠癌2/3期临床研究于中国境内完成首例患者给药

斯鲁利单抗 (PD-1) + HLX07 (EGFR) 2期IND获NMPA批准



斯鲁利单抗 (PD-1) + 化疗治疗食管鳞癌3期临床研究完成受试者招募入组

斯鲁利单抗 (PD-1) + 化疗治疗广泛期小细胞肺癌3期临床研究达到主要研究终点

HLX04-O (VEGF) 治疗湿性年龄相关性黄斑变性3期IND获澳大利亚、美国、拉脱维亚、新加坡、西班牙、捷克、波兰等欧盟国家批准

HLX22 (HER2) + 汉曲优® (HER2) 治疗胃癌2期临床研究完成首例患者给药

HLX26 (LAG-3) 治疗实体瘤及淋巴瘤治疗的1期临床研究完成首例受试者给药





Disclaimer

Henlius, the representor or the provider does not make express or implied warranties, statements or representations on the content of this document (the content of this document may also include forward-looking statements), including but not limited to the statements about the timeliness, universality and accuracy of the content for any specific purpose or with regard to the correctness of the information obtained by using the content of this document. If any conduct or consequence is caused due to any mistake, omission or incorrectness of relevant content, Henlius, the representor or the provider shall not be liable.

All rights, including copyrights, of this document and the content contained herein shall be exclusively owned by Henlius, among which the relevant words "Henlius" and "复宏汉霖", patterns and relevant logos are the names, trademarks and logos legally owned by Henlius. No third party could use them by any means including reproduction without written consent from Henlius.

The content of this document does not include and shall not be deemed as any advice (including but not limited to medical advice and investment advice). You shall be liable for any decision made by yourself based on the content of this document.

